Dr Vladislav Sandler, chief executive of PLC (), caught up with Proactive's Andrew Scott while in London to meet with investors.
It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations with leading universities and pharmaceutical companies.
Dr Sandler says all is on track and work is “progressing successfully” towards the goal of submitting an investigational new drug application to the US Food and Drug Administration for their CDX antibodies product.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE